title: [Fibrinolytic treatment].
authors.forename: E
authors.initials: E
authors.lastname: Zemp
authors.forename: M T
authors.initials: MT
authors.lastname: Widmer
authors.forename: H E
authors.initials: HE
authors.lastname: Schmitt
authors.forename: G A
authors.initials: GA
authors.lastname: Marbet
authors.forename: F
authors.initials: F
authors.lastname: Duckert
authors.forename: L K
authors.initials: LK
authors.lastname: Widmer
mesh_terms: D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000008:administration & dosage; D013300:Streptokinase / Q000008:administration & dosage; D013924:Thrombophlebitis / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase; D010644:Phenprocoumon
vernacular_title: Medikamentöse Fibrinolyse.